DrugPatentWatch Database Preview
Oxaprozin - Generic Drug Details
What are the generic drug sources for oxaprozin and what is the scope of oxaprozin patent protection?
Oxaprozin
is the generic ingredient in three branded drugs marketed by Gd Searle, Actavis Elizabeth, Amneal Pharms Co, Apotex Inc, Dr Reddys Labs Ltd, Ivax Sub Teva Pharms, Mylan, Mylan Pharms Inc, Sandoz, Sun Pharm Inds Inc, Teva, and Watson Labs, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.There are thirteen drug master file entries for oxaprozin. Nineteen suppliers are listed for this compound.
Summary for oxaprozin
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 12 |
| NDAs: | 15 |
| Drug Master File Entries: | 13 |
| Suppliers / Packagers: | 19 |
| Bulk Api Vendors: | 78 |
| Clinical Trials: | 4 |
| Patent Applications: | 6,871 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for oxaprozin |
| DailyMed Link: | oxaprozin at DailyMed |
Pharmacology for oxaprozin
| Ingredient-type | Nonsteroidal Anti-inflammatory Compounds |
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
Synonyms for oxaprozin
| .beta.-(4,5-Diphenyloxazol-2-yl)propionic acid |
| 2-Oxazolepropanoic acid, 4,5-diphenyl- |
| 2-Oxazolepropanoic acid,5-diphenyl- |
| 2-OXAZOLEPROPIONIC ACID, 4,5-DIPHENYL- |
| 2-Oxazolepropionic acid,5-diphenyl- |
| 21256-18-8 |
| 256O188 |
| 3-(4, 5-Diphenyl-2-oxazo |
| 3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid |
| 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid |
| 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid # |
| 3-(4,5-Diphenyl-2-oxazolyl)propanoic acid |
| 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid |
| 3-(4,5-Diphenyl-2-oxazolyl)propionic acid |
| 3-(4,5-Diphenyl-oxazol-2-yl)-propionic acid |
| 3-(4,5-Diphenyloxazol-2-yl)propanoic acid |
| 3-(diphenyl-1,3-oxazol-2-yl)propanoic acid |
| 4, 5-Diphenyl-2-oxazolepropionic acid |
| 4,5-Diphenyl-2-oxazolepropanoic acid |
| 4,5-Diphenyl-2-oxazolepropionic acid |
| 4,5-diphenyloxazole-2-propanoic acid |
| 4.5-Diphenyl-2-oxazolepropanoic acid|||Daypro |
| A815225 |
| AB0011812 |
| AB00514024 |
| AB00514024_08 |
| AB00514024_09 |
| AC-26512 |
| AC1L1IK7 |
| AC1Q759J |
| AC1Q759K |
| Actirin |
| AJ-08102 |
| AK-84489 |
| AKOS000206807 |
| Alvo |
| ANW-63377 |
| Apo-Oxaprozin |
| Apotex brand of oxaprozin |
| B1804 |
| BDBM50002861 |
| beta-(4,5-Diphenyloxazol-2-yl)propionic acid |
| BIDD:GT0438 |
| BIDD:PXR0149 |
| BPBio1_001122 |
| BRD-K25394294-001-05-7 |
| BRN 1083168 |
| BSPBio_001020 |
| BSPBio_002696 |
| C07356 |
| C18H15NO3 |
| CAS-21256-18-8 |
| CCG-36508 |
| CHEBI:7822 |
| CHEMBL1071 |
| CPD000058286 |
| CS-7975 |
| CSC brand of oxaprozin |
| CTK7J3117 |
| D00463 |
| D0M9DC |
| Danoprox |
| Daypro |
| Daypro (TN) |
| Dayrun |
| DB00991 |
| Deflam |
| DSSTox_CID_25118 |
| DSSTox_GSID_45118 |
| DSSTox_RID_80684 |
| DTXSID1045118 |
| Durapro |
| Duraprost |
| Duraprox (TN) |
| EINECS 244-296-1 |
| EN300-25629 |
| EU-0100944 |
| FT-0638104 |
| GTPL7252 |
| HE004392 |
| HE274938 |
| HMS1571C22 |
| HMS1922P17 |
| HMS2051L15 |
| HMS2093O08 |
| HMS2098C22 |
| HMS3262N10 |
| HMS3393L15 |
| HMS3652H17 |
| HMS566H22 |
| HSDB 7586 |
| HY-B0808 |
| I14-8703 |
| J-013955 |
| J10396 |
| K-6109 |
| KB-59357 |
| KBio3_001916 |
| KBioGR_001722 |
| KS-00000ULR |
| KS-5196 |
| Lopac-O-9637 |
| Lopac0_000944 |
| LP00944 |
| LS-100216 |
| lyl)propenoic acid |
| Maybridge1_008800 |
| MCULE-7099031811 |
| MFCD00215977 |
| MHJ80W9LRB |
| MLS000759535 |
| MLS001424072 |
| MolPort-000-146-829 |
| NC00214 |
| NCGC00014711 |
| NCGC00014711-01 |
| NCGC00014711-02 |
| NCGC00014711-03 |
| NCGC00014711-04 |
| NCGC00014711-05 |
| NCGC00014711-06 |
| NCGC00014711-07 |
| NCGC00014711-08 |
| NCGC00014711-09 |
| NCGC00014711-10 |
| NCGC00014711-11 |
| NCGC00014711-14 |
| NCGC00094249-01 |
| NCGC00094249-02 |
| NCGC00094249-03 |
| NCGC00094249-04 |
| NCGC00094249-05 |
| NCGC00094249-06 |
| NCGC00094249-07 |
| NCGC00261629-01 |
| NCI310839 |
| NCI60_002681 |
| NCIStruc1_000799 |
| NCIStruc2_000787 |
| NSC 310839 |
| NSC-310839 |
| NSC-758949 |
| NSC310839 |
| NSC758949 |
| O 9637 |
| O0377 |
| OFPXSFXSNFPTHF-UHFFFAOYSA-N |
| Oprea1_509470 |
| Oxapro |
| oxaprosin |
| Oxaprozi |
| Oxaprozin (JP15/USAN/INN) |
| Oxaprozin (JP17/USAN/INN) |
| Oxaprozin [USAN:BAN:INN:JAN] |
| Oxaprozin, solid |
| Oxaprozin, United States Pharmacopeia (USP) Reference Standard |
| Oxaprozina |
| Oxaprozina [INN-Spanish] |
| Oxaprozine |
| Oxaprozine [INN-French] |
| Oxaprozinum |
| Oxaprozinum [INN-Latin] |
| Pfizer brand of oxaprozin |
| Pharmakon1600-01505267 |
| Prestwick0_001060 |
| Prestwick1_001060 |
| Prestwick2_001060 |
| Prestwick3_001060 |
| Rhoxal-oxaprozin |
| Rhoxalpharma brand of oxaprozin |
| s4230 |
| SAM001246770 |
| SBB053166 |
| SBI-0050918.P002 |
| SC-13926 |
| SCHEMBL3286 |
| SMR000058286 |
| SPBio_001652 |
| SPBio_002940 |
| SPECTRUM1505267 |
| Spectrum2_001696 |
| Spectrum3_001078 |
| Spectrum4_001231 |
| SR-01000076053-3 |
| ST50949623 |
| TC-152122 |
| Tox21_110059 |
| Tox21_110059_1 |
| Tox21_500944 |
| TRB brand of oxaprozin |
| UNII-MHJ80W9LRB |
| Voir |
| Walix |
| WY 21743 |
| WY-21,743 |
| WY-21743 |
| Xopane |
| Z217102860 |
| ZINC49643479 |
US Patents and Regulatory Information for oxaprozin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | OXAPROZIN | oxaprozin | TABLET;ORAL | 075842-001 | Apr 12, 2001 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Sandoz | OXAPROZIN | oxaprozin | TABLET;ORAL | 075850-001 | Apr 27, 2001 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Amneal Pharms Co | OXAPROZIN | oxaprozin | TABLET;ORAL | 208633-001 | May 4, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: